Enhertu granted Priority Review for HER2m NSCLC
19 April 2022 07:00 BST Enhertugranted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer Based on pivotal DESTINY-Lung01 results showing AstraZeneca and Daiichi Sankyo's Enhertu demonstrated a 54.9% tumour response rate If approved, Enhertu to provide patients with a much-needed targeted therapy option AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with